



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 14 Nov 2016 (#39)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov).

Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa Coetsee [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)) **as soon as possible to inform of your intent to apply and then confirm at least 30 days before the submission date**. The NIH grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.**

## Important Notices:

- **Notice of Extension of Application Due Dates for PAR-16-052 " Global Noncommunicable Diseases and Injury Across the Lifespan: Exploratory Research (R21)"** ([NOT-TW-17-001](#))
- **Request for Information (RFI): Effects of Extrinsic Environmental Factors on Animal Research: Rigor and Reproducibility** ([NOT-OD-17-011](#))

## 1. Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** ([RFA-CA-17-010](#))

**Type:** R21

**Application Due Date:** February 28, 2017; May 26, 2017; September 26, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

**Purpose:** This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology.

This funding opportunity is part of a broader NCI-sponsored [Innovative Molecular Analysis Technologies \(IMAT\) Program](#).

**Budget:** NCI intends to commit \$5,000,000 in FY2018 to fund 22-24 awards. Direct costs are limited to \$400,000 over a 3-year period, with no more than \$200,000 in direct costs allowed in any single year. Application budgets must reflect the actual needs of the proposed project. The total project period request may not exceed 3 years.

## 2. Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** ([RFA-CA-17-011](#))

**Type:** R33

**Application Due Date:** February 28, 2017; May 26, 2017; September 26, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

**Purpose:** This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored [Innovative Molecular Analysis Technologies \(IMAT\) Program](#).

**Budget:** NCI intends to commit \$4,000,000 in FY2018 to fund an estimated 10 awards. Direct costs are limited to \$300,000 per year. Application budgets must reflect actual needs of the proposed project. The total project period request may not exceed 3 years.

### 3. Innovative Technologies for Cancer-Relevant Biospecimen Science

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-CA-17-012\)](#)

**Type:** R21

**Application Due Date:** Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

**Purpose:** This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored [Innovative Molecular Analysis Technologies \(IMAT\) Program](#).

**Budget:** NCI intends to commit \$1,200,000 in FY2018 to fund an estimate of 5 awards. Direct costs are limited to \$400,000 over a 3-year period, with no more than \$200,000 in direct costs allowed in any single year. Application budgets must reflect the actual needs of the proposed project. The total project period request may not exceed 3 years.

### 4. Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-CA-17-013\)](#)

**Type:** R33

**Application Due Date:** February 28, 2017; May 26, 2017; September 26, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

**Purpose:** This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored [Innovative Molecular Analysis Technologies \(IMAT\) Program](#).

**Budget:** NCI intends to commit \$800,000 in FY2018 to fund an estimated 2 awards. Direct costs are limited to \$300,000 per year. Application budgets must reflect actual needs of the proposed project. The total project period request may not exceed 3 years.

**Brief definitions of some NIH grant mechanisms:** [comprehensive list of extramural grant and cooperative agreement activity codes](#)

**D71 - International Research Training Planning Grant:** To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

**D43 - International Research Training Grants:** To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

**R01 - NIH Research Project Grant Program:** most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

**R21 - NIH Exploratory/Developmental Research Grant:** encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

**R03 - NIH Small Grant Program:** limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

**R21/R33 - Phased Innovation:** The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

**R25 - NIH Education Projects:** used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

**R34 - Clinical Trial Planning Grant Program:** To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

**R35 - Outstanding Investigator Award:** To provide long term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential.

**U01 - NIH Research Project Cooperative Agreement:** supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

**U24 - Resource-Related Research Projects - Cooperative Agreements:** To support research projects contributing to improvement of the capability of resources to serve biomedical research.

**U01 - NIH Research Project Cooperative Agreement:** supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

**U19 - Research Program-Cooperative Agreements:** supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

[Glossary of selected acronyms:](#)

**FOA** Funding Opportunity Announcement

**PA** Program Announcements (*click on "PA" to search for further funding opportunities*)

**RFA** Request for Applications (*click on "RFA" to search for further funding opportunities*)

Complete [Glossary and acronym list of NIH Terms](#)



Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus. • Enquiries: **Dr Christa Coetsee** • Tel: 9838 • Email: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)